Header

UZH-Logo

Maintenance Infos

Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary


Achtnichts, L; Chan, A; Czaplinski, A; Derfuss, T; Du Pasquier, R; Findling, O; Gobbi, C; Hoepner, R; Kamber, N; Kamm, CP; Kuhle, J; Lalive, P; Lutterotti, A; Martin, R; Müller, S; Papadopoulou, A; Pot, C; Salmen, A; Schippling, S; Zecca, C (2019). Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clinical and Translational Neuroscience, 3(1):2514183X1882207.

Abstract

More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS). However, for some substances, there is a clear difference between approval in Switzerland (Swissmedic) and neighboring countries (European Medicines Agency (EMA)). In addition, limitations imposed by the Swiss Federal Office of Public Health in the specialties list (SL) have significant effects on use in daily clinical practice. In the following, we present consensus recommendations, which were reviewed and agreed upon by the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. We explicitly focus on practice-relevant differences in the approval of MS immunotherapies in Switzerland compared with the EMA area and discuss further limitations (SL) and their impact on the use in clinical practice. Immunotherapies with the same approval in Switzerland and the EMA area and symptomatic therapies are not discussed here.

Abstract

More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS). However, for some substances, there is a clear difference between approval in Switzerland (Swissmedic) and neighboring countries (European Medicines Agency (EMA)). In addition, limitations imposed by the Swiss Federal Office of Public Health in the specialties list (SL) have significant effects on use in daily clinical practice. In the following, we present consensus recommendations, which were reviewed and agreed upon by the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. We explicitly focus on practice-relevant differences in the approval of MS immunotherapies in Switzerland compared with the EMA area and discuss further limitations (SL) and their impact on the use in clinical practice. Immunotherapies with the same approval in Switzerland and the EMA area and symptomatic therapies are not discussed here.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

10 downloads since deposited on 09 Aug 2019
10 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 January 2019
Deposited On:09 Aug 2019 07:40
Last Modified:25 Sep 2019 00:39
Publisher:Sage Publications Ltd.
ISSN:2514-183X
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1177/2514183x18822073

Download

Download PDF  'Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary'.
Preview
Content: Published Version
Filetype: PDF
Size: 218kB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)